Famotidine

xPharm: The Comprehensive Pharmacology Reference

Volumn , Issue , 2007, Pages 1-5

  Jewell, Richard ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884088515     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008055232-3.61738-6     Document Type: Chapter

References (13)

1. Barzaghi N., Gatti G., Crema F., Perucca E. Impaired bioavailability of famotidine given concurrently with a potent antacid. J. Clin. Pharmacol. 1989, 29(7):670-672.
2. Berardi R.R., Tankanow R.M., Noratrant T.T. Comparison of famotidine with cimetidine and ranitidine. Clin. Pharmacol. 1988, 7:271-284.
3. Burek J.D., Majka J.A., Bokeman D.L. Famotidine: summary of preclinical safety assessment. Digestion 1985, 32(Suppl 1):7-14.
4. Campoli-Richards D.M., Clissold S.P. Famotidine: Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986, 32(3):197-221.
5. Gitlin N., McCullough A.J., Smith J.L., Mantell G., Berman R. A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. Gastroenterology 1987, 92:48-53.
6. Inotsume N., Nishimura M., Nakano M., Fujiyama S., Sato T. The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J. Clin. Pharmacol. 1990, 30(1):50-56.
7. Simon T., Berlin R., Tippig R., Gilda L. Efficacy of twice daily doses of 40 mg or 20 mg famotidine or 150 mg ranitidine for treatment of patients with moderate to severe erosive esophagitis. Scan. J. Gastroenterol. 1993, 28:375-380.
8. Dollery C. Famotidine. Therapeutic Drugs 1999, F14-F18. Churchill-Livingston, UK. Edition 2. C. Dollery (Ed.).
9. Gastro-Intestinal System. British National Formulary (BNF) 2002, 39. British National Formulary, British Medical Association, UK. Edition 43.
10. Sweetman S.C. Gastrointestinal Drugs. Martindale - The Complete Drug Reference 2002, 1225-1227. Pharmaceutical Press, UK. Edition 33. S.C. Sweetman (Ed.).
11. O'Neil M.J., Smith A., Heckelman P.E. Famotidine. The Merck Index 2001, 696. Merck Research Laboratories, USA. Edition 13. M.J. O'Neil, A. Smith, P.E. Heckelman (Eds.).
12. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Eds. J. G. Hardman, L. E. Limbird, and A. Goodman Gilman, 10th edition, 2001. Authorative reference covering the chemistry, pharmacology and therapeutic application of drugs.
13. Howden, C. W. and Tytgat, G.N.T., Review. The tolerability and safety profile of famotidine, Clinical Therapeutics, 18(1) (1996) 36-54. A comprehensive safety profile of oral famotidine, incorporating data from investigational trials, post-marketing studies and reports of marketed use.